Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allenex, AnaMar deal

This month, Allenex will sell its 2.1% equity

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE